Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

about

Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters.

P2860

Q47141268-0EF88473-21BD-418A-80B2-E3863A19B10C

P2860

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

Item

http://www.wikidata.org/entity/Q42362272

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

@en

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

@nl

type

Item

label

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

@en

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

@nl

prefLabel

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

@en

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

@nl

P1476

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition

@en

P2093

Florian Puhm

http://www.w3.org/2001/XMLSchema#string

Qiong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors

Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer

Hsp90 molecular chaperone inhibitors: are we there yet?

P2888

s00280-017-3390-x

P304

673-684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3390-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christian Nanoff

Michael Freissmuth

P577

2017-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090995337

http://www.w3.org/2001/XMLSchema#string

P698

28779264

http://www.w3.org/2001/XMLSchema#string

P921

AVP

P932

5608778

http://www.w3.org/2001/XMLSchema#string

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

about

P2860

P2860

Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932